Skip to main content
. 2022 Mar 24;13:850015. doi: 10.3389/fimmu.2022.850015

Figure 4.

Figure 4

ELISA validation of selected ICx in an independent cohort of LN patients. (A) A total of 83 serum samples from healthy controls (N = 21, blue), inactive LN (N = 13, green), and active LN (N = 49, red) were tested by sandwich ELISA for immune complex levels of BST1, CD14, CD34, CSTA, FN1, MEF2C, P3H1, PHACTR4, RGS12, and UBC. Asterisks designate the level of statistical significance: *p < 0.05, **p < 0.01, ****p < 0.0001, using the Wilcoxon test. (B) Principal component analysis (PCA) of 10 ICx among HC, inactive LN, and active LN individuals. The two first principal components (PC1, PC2) were plotted. (C) The discriminatory abilities of the 10 ICx in distinguishing LN patients from healthy control were examined using ROC analysis. (D) Using LASSO regression analysis, the ICx were combined into panels to distinguish LN patients from healthy control or active LN from inactive LN.

HHS Vulnerability Disclosure